Session

IBD (Posters)

CANNABIS INDUCES SIGNIFICANT CLINICAL AND QOL IMPROVEMENT IN CHRONIC POUCHITIS
CANNABIS INDUCES SIGNIFICANT CLINICAL AND QOL IMPROVEMENT IN CHRONIC POUCHITIS

IBD (Posters)  et al.

INCIDENCE AND RISK FACTORS FOR NEOPLASIA IN INFLAMMATORY BOWEL DISEASE
INCIDENCE AND RISK FACTORS FOR NEOPLASIA IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU
EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU

IBD (Posters)  et al.

INTRAABDOMINAL ABSCESSES IN CROHN'S DISEASE: TREATMENT AND OUTCOMES
INTRAABDOMINAL ABSCESSES IN CROHN'S DISEASE: TREATMENT AND OUTCOMES

IBD (Posters)  et al.

IMPROVEMENT IN PATIENT ACTIVATION MEASURE (PAM) IS SEEN FOLLOWING A FOCUSED FRAMEWORK OF EDUCATION IN A NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE COHORT
IMPROVEMENT IN PATIENT ACTIVATION MEASURE (PAM) IS SEEN FOLLOWING A FOCUSED FRAMEWORK OF EDUCATION IN A NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE COHORT

IBD (Posters)  et al.

SERIOUS ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: WHO IS MOST AT RISK?
SERIOUS ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: WHO IS MOST AT RISK?

IBD (Posters)  et al.

REAL-TIME USE OF ARTIFICIAL INTELLIGENCE DURING COLONOSCOPY PREDICTS RELAPSE OF ULCERATIVE COLITIS: A PROSPECTIVE STUDY
REAL-TIME USE OF ARTIFICIAL INTELLIGENCE DURING COLONOSCOPY PREDICTS RELAPSE OF ULCERATIVE COLITIS: A PROSPECTIVE STUDY

IBD (Posters)  et al.

ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OF PERSISTENT HISTOLOGICAL ACTIVITY DESPITE ENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITH BIOLOGICS
ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OF PERSISTENT HISTOLOGICAL ACTIVITY DESPITE ENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITH BIOLOGICS

IBD (Posters)  et al.

PHARMACOKINETIC AND NONCLINICAL SAFETY EVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, IN NON-HUMAN PRIMATES
PHARMACOKINETIC AND NONCLINICAL SAFETY EVALUATION OF SZN-1326, A WNT SIGNAL ACTIVATOR, IN NON-HUMAN PRIMATES

IBD (Posters)  et al.

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL
COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

IBD (Posters)  et al.

ANTIOXIDANT VITAMINS AND ELECTROLYTES INCREASED INTAKE IS ASSOCIATED WITH LOWER DISEASE ACTIVITY AND BETTER QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
ANTIOXIDANT VITAMINS AND ELECTROLYTES INCREASED INTAKE IS ASSOCIATED WITH LOWER DISEASE ACTIVITY AND BETTER QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZE LUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS
HUMAN INTESTINAL EPITHELIAL CELLS INTERNALIZE LUMINAL FUNGI VIA LC3-ASSOCIATED PHAGOCYTOSIS

IBD (Posters)  et al.

THE IBD DISK IS WELL CORRELATED WITH ENDOSCOPIC AND BIOMARKER EVIDENCE OF INFLAMMATION IN CROHN'S DISEASE PATIENTS
THE IBD DISK IS WELL CORRELATED WITH ENDOSCOPIC AND BIOMARKER EVIDENCE OF INFLAMMATION IN CROHN'S DISEASE PATIENTS

IBD (Posters)  et al.

SERUM LEVELS OF INFLIXIMAB AND ADALIMUMAB BIOSIMILARS CAN BE MEASURED EQUIVALENTLY TO ORIGINATOR DRUGS BY QUANTUM BLUE RAPID TESTING AS TOOL FOR THERAPEUTIC DRUG MONITORING
SERUM LEVELS OF INFLIXIMAB AND ADALIMUMAB BIOSIMILARS CAN BE MEASURED EQUIVALENTLY TO ORIGINATOR DRUGS BY QUANTUM BLUE RAPID TESTING AS TOOL FOR THERAPEUTIC DRUG MONITORING

IBD (Posters)  et al.

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

IBD (Posters)  et al.

MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

IBD (Posters)  et al.

UNTARGETED SERUM METABOLOME IN LONGITUDINAL CROHN'S DISEASE (CD) COHORT ENROLLED DURING REMISSION SHOWS STRONG INDIVIDUALIZED SIGNATURE AND CD-ASSOCIATED SIGNALS THAT ARE MAINTAINED ALSO IN PATIENTS WHO NORMALIZED THEIR FECAL CALPROTECTIN
UNTARGETED SERUM METABOLOME IN LONGITUDINAL CROHN'S DISEASE (CD) COHORT ENROLLED DURING REMISSION SHOWS STRONG INDIVIDUALIZED SIGNATURE AND CD-ASSOCIATED SIGNALS THAT ARE MAINTAINED ALSO IN PATIENTS WHO NORMALIZED THEIR FECAL CALPROTECTIN

IBD (Posters)  et al.

REAL-WORLD IMPACT OF BIOLOGICAL THERAPIES ON WORK IMPAIRMENT AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE PATIENTS
REAL-WORLD IMPACT OF BIOLOGICAL THERAPIES ON WORK IMPAIRMENT AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE PATIENTS

IBD (Posters)  et al.

DE-ESCALATION OF BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING PRIOR ESCALATION
DE-ESCALATION OF BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING PRIOR ESCALATION

IBD (Posters)  et al.

Item 441 - 460 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
23
24 25 26 27 28 29